Best Monkeypox Stocks to Watch if Outbreak Continues
The monkeypox outbreak is raising red flags for the American healthcare system. In fact, vaccines and antiviral treatments are hard to come by at the current moment. This is why investors are pinpointing specific companies that are prepared to help fight the virus. The best monkeypox stocks have a head start making vaccines and providing antiviral treatment.
Cases are rising throughout the world due to international travel and the scarcity of proper treatment. Therefore, which companies are beginning to develop vaccines and antiviral medications to fight this growing threat? Let’s take a closer look at monkeypox and the companies that are preparing to make a difference.
The Best Monkeypox Stocks: How Did We Get Here?
Believe it or not, monkeypox was first discovered in 1958 when a disease was recognized in monkeys kept for research in Copenhagen, Denmark. According to the CDC, it’s a rare disease that is caused by infection with the monkeypox virus.
The first human case was recorded in 1970. In addition, most cases since have come within Africa. Cases outside of Africa began to appear due to international travel and the importation of animals.
Now there are outbreaks around the world and the spread doesn’t seem to be slowing down. However, there are a limited amount of vaccines available. This is why you may want to keep a close watch on the companies that are on the frontlines of treatment. Below are the best monkeypox stocks to invest in right now.
3. Moderna Inc (Nasdaq: MRNA)
Moderna is the creator of one of the most prominent COVID-19 vaccines in America. However, it’s also beginning to investigate the “potential of monkeypox vaccines at a preclinical level,” according to a recent post on its Twitter account.
This is huge news, as Moderna is already one of the biggest players in the biotech space. Along with its production of COVID-19 vaccines and booster shots, Moderna may be the perfect fit for your portfolio. It’s down more than 50% in the past year and is trading around $160 at the moment. With a 52-week high of $497.49, buying low is tempting many investors who are looking for the best monkeypox stocks moving forward.
2. Emergent Biosolutions (NYSE: EBS)
Emergent Biosolutions is a Maryland-based biopharmaceutical company. And it makes the top of this list due to its smallpox vaccine, ACAM2000®. Specifically, ACAM2000® is expected to be effective against monkeypox due to its close relation to the variola virus. This is the same virus that causes smallpox.
Moreover, a recent announcement is giving Emergent more leverage and power as the monkeypox outbreak continues to surge. The company is acquiring the rights to TEMBEXA®, a smallpox antiviral treatment, in a $225 million deal with Chimerix (Nasdaq: CMRX).
The viability of smallpox treatments for use against monkeypox is gaining steam. And this is why Emergent is one of the best monkeypox stocks to consider right now. It’s trading around $34 at the moment and it’s up roughly 10% in the past month.
Keep Reading This Article and Find Out the Best Monkeypox Stock Right Now
Enter your email below to reveal the best monkeypox stock on this list.
You’ll also be opted in to receive our free daily e-letter, Investment U, where you’ll find expert investment insight, analysis and stock picks for all the best investment opportunities.
Nunc ut lorem quis urna auctor ornare quis in sem. Donec sodales viverra ante, et scelerisque libero iaculis sit amet. Phasellus fermentum vitae tellus quis suscipit. Ut bibendum aliquet odio, a venenatis augue fermentum at. Nunc fringilla dui lorem, congue blandit ex egestas in. Vestibulum dapibus orci ut felis consequat euismod. Sed pretium, risus vel blandit porttitor, diam diam sodales dui, in lobortis lorem ex vitae est. Nullam ac venenatis massa. Integer blandit, diam et fringilla semper, nulla dui suscipit urna, eget hendrerit quam ex rutrum tellus. Nam imperdiet, nibh nec mollis vulputate, felis ante posuere leo, at ultrices nulla neque vitae mi.Nunc ut lorem quis urna auctor ornare quis in sem. Donec sodales viverra ante, et scelerisque libero iaculis sit amet. Phasellus fermentum vitae tellus quis suscipit. Ut bibendum aliquet odio, a venenatis augue fermentum at. Nunc fringilla dui lorem, congue blandit ex egestas in. Vestibulum dapibus orci ut felis consequat euismod. Sed pretium, risus vel blandit porttitor, diam diam sodales dui, in lobortis lorem ex vitae est. Nullam ac venenatis massa. Integer blandit, diam et fringilla semper, nulla dui suscipit urna, eget hendrerit quam ex rutrum tellus. Nam imperdiet, nibh nec mollis vulputate, felis ante posuere leo, at ultrices nulla neque vitae mi.
Integer blandit, diam et fringilla semper, nulla dui suscipit urna, eget hendrerit quam ex rutrum tellus. Nam imperdiet, nibh nec mollis vulputate, felis ante posuere leo, at ultrices nulla neque vitae mi.Nunc ut lorem quis urna auctor ornare quis in sem. Donec sodales viverra ante, et scelerisque libero iaculis sit amet. Phasellus fermentum vitae tellus quis suscipit. Ut bibendum aliquet odio, a venenatis augue fermentum at. Nunc fringilla dui lorem, congue blandit ex egestas in. Vestibulum dapibus orci ut felis consequat euismod. Sed pretium, risus vel blandit porttitor, diam diam sodales dui, in lobortis lorem ex vitae est. Nullam ac venenatis massa. Integer blandit, diam et fringilla semper, nulla dui suscipit urna, eget hendrerit quam ex rutrum tellus. Nam imperdiet, nibh nec mollis vulputate, felis ante posuere leo, at ultrices nulla neque vitae mi.
1. Bavarian Nordic (OTC: BVNRY)
Bavarian Nordic is a vaccine company at the forefront of the monkeypox battle. This biotech company focuses on the development, manufacturing and commercialization of vaccines for infectious diseases and immunotherapies for certain cancers.
In fact, this small Danish company is the sole supplier of the only licensed monkeypox vaccine available today. And that’s why it has to make every monkeypox stocks list.
Bavarian Nordic has inked a deal with the U.S. for more than seven million doses of the Jynneos monkeypox shot over the next year. There are also deals in place with various other countries facing outbreaks. And you can expect the U.S. to expand on this deal if necessary.
At the current moment, Bavarian Nordic stock is trading over-the-counter for more than $16 a share. Its value is skyrocketing since the monkeypox outbreak began. It was trading around $5 in May of 2022.
[/gated-c0ntent]
Investing in Biotech Stocks
Biotech stocks are facing high volatility, like much of the market right now. However, the companies above are best placed to help fight the monkeypox virus as outbreaks continue to surge.
For more stock analysis, you may want to sign up for one of the best investment newsletters by market experts. These free e-letters provide stock tips and insights that may help you protect your portfolio during a bear market and enhance its potential for the future.
The best monkeypox stocks will be ready to meet treatment and vaccine supply as demand continues to grow. Add these stocks to your watch list as potential investment opportunities if the virus outbreak gets out of control.
